Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Moderate Buy" from Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $16.90.

Several brokerages recently weighed in on ROIV. Deutsche Bank Aktiengesellschaft raised their price target on shares of Roivant Sciences from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Wednesday. Wolfe Research began coverage on shares of Roivant Sciences in a research report on Thursday, February 15th. They issued an "outperform" rating and a $17.00 target price for the company. TheStreet raised shares of Roivant Sciences from a "d" rating to a "c+" rating in a research report on Tuesday, February 13th. Bank of America lifted their target price on shares of Roivant Sciences from $11.00 to $12.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 2nd. Finally, HC Wainwright lifted their target price on shares of Roivant Sciences from $17.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday.

Insider Transactions at Roivant Sciences

In other news, COO Eric Venker sold 96,950 shares of Roivant Sciences stock in a transaction on Friday, February 9th. The shares were sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the transaction, the chief operating officer now owns 532,207 shares in the company, valued at approximately $5,811,700.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.60% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ROIV. Bank of New York Mellon Corp lifted its stake in shares of Roivant Sciences by 10.1% during the 1st quarter. Bank of New York Mellon Corp now owns 47,274 shares of the company's stock valued at $233,000 after buying an additional 4,335 shares in the last quarter. Citigroup Inc. lifted its stake in shares of Roivant Sciences by 1,803.6% during the 1st quarter. Citigroup Inc. now owns 5,749 shares of the company's stock valued at $28,000 after buying an additional 5,447 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Roivant Sciences by 3.0% during the 1st quarter. BlackRock Inc. now owns 4,044,419 shares of the company's stock valued at $19,980,000 after buying an additional 117,329 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Roivant Sciences by 13.8% during the 1st quarter. Vanguard Group Inc. now owns 1,319,499 shares of the company's stock valued at $6,519,000 after buying an additional 159,787 shares in the last quarter. Finally, American International Group Inc. purchased a new position in shares of Roivant Sciences during the 1st quarter valued at $8,965,000. Hedge funds and other institutional investors own 64.76% of the company's stock.

Roivant Sciences Stock Up 5.4 %

Shares of ROIV traded up $0.59 on Wednesday, hitting $11.51. 21,727,908 shares of the stock traded hands, compared to its average volume of 7,223,655. The company has a market capitalization of $9.28 billion, a PE ratio of 2.21 and a beta of 1.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 27.79 and a current ratio of 27.79. The business has a 50 day simple moving average of $10.78 and a 200 day simple moving average of $10.36. Roivant Sciences has a one year low of $6.97 and a one year high of $13.24.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings results on Tuesday, February 13th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.07. The company had revenue of $37.14 million during the quarter, compared to the consensus estimate of $30.72 million. Roivant Sciences had a net margin of 3,624.14% and a negative return on equity of 33.38%. As a group, equities analysts forecast that Roivant Sciences will post -1.36 earnings per share for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.